4SC AG: 4SC publishes Q1 2024 report
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
In den vergangenen zwei Jahrzehnten hat sich das wissenschaftliche Interesse verstärkt auf Exosome gerichtet – kleine ex…
Gold is not only an excellent means of preserving value for investors but is also becoming increasingly important in med…
NurExone Biologic Inc. (TSXV: NRX) (Deutschland: J90) (das "Unternehmen" oder "NurExone"), ein bahnbrechendes biopharmaz…
ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in t…
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…